A new study by researchers at the University of Eastern Finland shows for the first time that blood-based measurement of glial fibrillary acidic protein (GFAP) enables distinguishing patients with frontotemporal dementia from those with primary psychiatric disorders or healthy individuals.
SmartSleep Lab is a new research laboratory to be set up in the Department of Applied Physics at the University of Eastern Finland. Relying on the principles of open science, the laboratory will provide a unique setting for sleep research and a versatile testbed for the health technology sector.
In the future, a growing number of neurodegenerative diseases could ideally be treated with the same drug, says Timo Myöhänen, the University of Eastern Finland’s newly appointed Professor of Pharmacology and Drug Development.
The University of Eastern Finland is a partner in a new, six-year project focusing on knee osteoarthritis, which has been granted approximately 6.7 million euros of funding by the Novo Nordisk Foundation. UEF’s share of the funding amounts to 1.4 million euros.